Atrix pries open huge dental medical market

FORT COLLINS – It’s been a decade-long journey, but Atrix Laboratories Inc. now stands at the door of its destination as it awaits U.S. Food and Drug Administration approval to market Atridox, the company’s breakthrough product for the treatment of periodontal disease.

Federal approval of the product promises to transform a long-running entrepreneurial endeavor into a highly profitable company offering unique drug-delivery products with a host of applications.

A company analysis prepared this year by Montgomery Securities predicts that Atrix will generate sales of $25 million in 1998, rising to $160 million in 2001 – numbers that stand in sharp contrast to…